InterMune, Inc. - Product Pipeline Review - 2014

  • ID: 3056972
  • Company Profile
  • 40 pages
  • Global Markets Direct
1 of 4
InterMune, Inc. - Product Pipeline Review - 2014

Summary

This, ‘InterMune, Inc. - Product Pipeline Review - 2014’, provides an overview of the InterMune, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of InterMune, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of InterMune, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of InterMune, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the InterMune, Inc.’s pipeline products

Reasons to buy

- Evaluate InterMune, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of InterMune, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the InterMune, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of InterMune, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of InterMune, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of InterMune, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
InterMune, Inc. Snapshot
InterMune, Inc. Overview
Key Information
Key Facts
InterMune, Inc. - Research and Development Overview
Key Therapeutic Areas
InterMune, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
InterMune, Inc. - Pipeline Products Glance
InterMune, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
InterMune, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
InterMune, Inc. - Drug Profiles
pirfenidone
Product Description
Mechanism of Action
R&D Progress
ITMN-10534
Product Description
Mechanism of Action
R&D Progress
ITMN-14440
Product Description
Mechanism of Action
R&D Progress
ITMN-30162
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit LOXL2 for Fibrosis
Product Description
Mechanism of Action
R&D Progress
InterMune, Inc. - Pipeline Analysis
InterMune, Inc. - Pipeline Products by Target
InterMune, Inc. - Pipeline Products by Route of Administration
InterMune, Inc. - Pipeline Products by Molecule Type
InterMune, Inc. - Pipeline Products by Mechanism of Action
InterMune, Inc. - Recent Pipeline Updates
InterMune, Inc. - Dormant Projects
InterMune, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
interferon gamma-1b (recombinant)
InterMune, Inc. - Company Statement
InterMune, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
InterMune, Inc., Key Information
InterMune, Inc., Key Facts
InterMune, Inc. - Pipeline by Indication, 2014
InterMune, Inc. - Pipeline by Stage of Development, 2014
InterMune, Inc. - Monotherapy Products in Pipeline, 2014
InterMune, Inc. - Out-Licensed Products in Pipeline, 2014
InterMune, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
InterMune, Inc. - Phase II, 2014
InterMune, Inc. - Preclinical, 2014
InterMune, Inc. - Discovery, 2014
InterMune, Inc. - Pipeline by Target, 2014
InterMune, Inc. - Pipeline by Route of Administration, 2014
InterMune, Inc. - Pipeline by Molecule Type, 2014
InterMune, Inc. - Pipeline Products by Mechanism of Action, 2014
InterMune, Inc. - Recent Pipeline Updates, 2014
InterMune, Inc. - Dormant Developmental Projects,2014
InterMune, Inc. - Discontinued Pipeline Products, 2014
InterMune, Inc., Subsidiaries

List of Figures
InterMune, Inc. - Pipeline by Top 10 Indication, 2014
InterMune, Inc. - Pipeline by Stage of Development, 2014
InterMune, Inc. - Monotherapy Products in Pipeline, 2014
InterMune, Inc. - Pipeline by Top 10 Target, 2014
InterMune, Inc. - Pipeline by Top 10 Route of Administration, 2014
InterMune, Inc. - Pipeline by Top 10 Molecule Type, 2014
InterMune, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll